Drug Profile
Research programme: MRSA infection therapeutics - Asinex
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ASINEX
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 12 Jul 2016 Research programme: MRSA infection therapeutics - Asinex is available for licensing as of 12 Jul 2016. http://www.asinex.com
- 12 Jul 2016 Early research in Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route)